Education
About Us
Working with TipRanks
Follow Us
Zura Bio (ZURA)
NASDAQ:ZURA
ZURA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.97 - $6.35
Previous CloseN/A
Volume136.30K
Average Volume (3M)350.41K
Market Cap
$76.58M
Enterprise Value-$50.17K
Total Cash (Recent Filing)$176.50M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.51
Next Earnings
May 08, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding68,375,000
10 Day Avg. Volume517,193
30 Day Avg. Volume350,413
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$11.80Price Target Upside875.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Zura Bio News
PremiumCompany Announcements
Zura Bio Limited: 2024 Financial Results and Strategic Progress
PremiumCompany Announcements
Zura Bio to Participate in Global Healthcare ConferencePremiumCompany Announcements
Zura Bio Highlights Strategic Goals and Clinical Advances---
Bulls Say, Bears Say
Bulls Say
Clinical ProgressZURA plans to initiate a Phase 2 trial of lead asset tibulizumab in hidradenitis suppurativa (HS), and they now have an active IND for this indication.
Financial StabilityZura ended 2024 with roughly $176.5M in cash and cash equivalents, which management expects to provide an operational runway through 2027.
Regulatory InteractionsThe timely launch of the Phase 2 TibuSURE trial in systemic sclerosis aligns with ZURA's stated timeline, indicating positive interactions with the FDA.
Bears Say
Clinical Data ConcernsThere is a lackluster clinical data to date, with no clear dose-dependent response in B cell count reductions and an increase in IL-17A target engagement observed at the highest dose in the post-dosing follow-up period.
Market PerceptionZURA has fallen out of investor attention (-50% YTD vs. XBI -6.5%) in a dislocation largely driven by a perceived catalyst vacuum rather than any fundamental change to the story.
Regulatory RisksThe broader development-stage biotech landscape has seen heightened regulatory risks stemming from the recent FDA shakeup.
---
Ownership Overview
7.83% Insiders
2.90% Mutual Funds
46.12% Other Institutional Investors
38.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZURA FAQ
What was Zura Bio’s price range in the past 12 months?
Zura Bio lowest stock price was $0.97 and its highest was $6.35 in the past 12 months.
What is Zura Bio’s market cap?
Zura Bio’s market cap is $76.58M.
When is Zura Bio’s upcoming earnings report date?
Zura Bio’s upcoming earnings report date is May 08, 2025 which is in 24 days.
How were Zura Bio’s earnings last quarter?
Zura Bio released its earnings results on Mar 25, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.01.
Is Zura Bio overvalued?
According to Wall Street analysts Zura Bio’s price is currently Undervalued.
Does Zura Bio pay dividends?
Zura Bio does not currently pay dividends.
What is Zura Bio’s EPS estimate?
Zura Bio’s EPS estimate is -0.16.
How many shares outstanding does Zura Bio have?
Zura Bio has 68,375,000 shares outstanding.
What happened to Zura Bio’s price movement after its last earnings report?
Zura Bio reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went up 10.37%.
Which hedge fund is a major shareholder of Zura Bio?
Currently, no hedge funds are holding shares in ZURA
---
Zura Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.80 (875.21% Upside)
$11.80 (875.21% Upside)
Blogger Sentiment
Bullish
ZURA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 20.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.83%
12-Months-Change
Fundamentals
Return on Equity
-44.03%
Trailing 12-Months
Asset Growth
78.03%
Trailing 12-Months
Company Description
Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
---
ZURA Stock 12 Month Forecast
Average Price Target
$11.80
▲(875.21% Upside)
Technical Analysis
Best Analysts Covering ZURA
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-39.80%
reiterated a buy rating 20 days ago
Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -39.80% per trade.
---